Bio-Rad

OverviewSuggest Edit

Bio-Rad is a company that develops, manufactures, and sells a range of products and solutions for the life science research and clinical diagnostics markets. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. The Clinical Diagnostics segment designs, manufactures, sells test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market.
TypePublic
Founded1952
HQHercules, CA, USMap
Websitebio-rad.com
Employee Ratings3.5More
Overall CultureD+More
View Jobs (220)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2020)8,000(-1%)
Job Openings220
Revenue (FY, 2020)$2.5 B(+11%)
Share Price (Sept 2021)$802.9(+2%)
Cybersecurity ratingCMore

Key People/Management at Bio-Rad

Norman Schwartz

Norman Schwartz

Chairman of the Board, President and Chief Executive Officer
Michael Crowley

Michael Crowley

EVP, Global Commercial Operations
Tim Ernst

Tim Ernst

EVP, General Counsel & Secretary
Andrew Last

Andrew Last

Executive Vice President, Chief Operating Officer
Ilan Daskal

Ilan Daskal

Executive Vice President, Chief Financial Officer
Annette Tumolo

Annette Tumolo

Executive Vice President, President, Life Science Group
Show more

Bio-Rad Office Locations

Bio-Rad has offices in Hercules, Villa Ortúzar, Gladesville, Wien and in 64 other locations
Hercules, CA, US (HQ)
1000 Alfred Nobel Dr
Hercules, CA, US
2000 Alfred Nobel Dr
Hercules, CA, US
4000 Alfred Nobel Dr
Villa Ortúzar, AR
964 Estomba
Gladesville, AU
Level 5, 446 Victoria Road
Wien, AT
88 Hummelgasse
Show all (73)

Bio-Rad Financials and Metrics

Bio-Rad Revenue

Embed Graph
View revenue for all periods
Bio-Rad's revenue was reported to be $2.55 b in FY, 2020
USD

Revenue (Q1, 2021)

726.8m

Gross profit (Q1, 2021)

400.6m

Gross profit margin (Q1, 2021), %

55.1%

Net income (Q1, 2021)

977.4m

EBIT (Q1, 2021)

100.9m

Market capitalization (14-Sept-2021)

24.0b

Closing stock price (14-Sept-2021)

802.9

Cash (31-Mar-2021)

673.5m

EV

23.6b
Bio-Rad's current market capitalization is $24 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

2.0b2.1b2.2b2.3b2.3b2.5b

Revenue growth, %

(7%)2%4%6%

Cost of goods sold

897.8m930.1m972.8m1.1b1.1b1.1b

Gross profit

1.1b1.1b1.2b1.2b1.3b1.4b
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

471.2m516.8m508.7m500.1m504.7m535.0m551.5m575.9m545.1m554.0m572.6m560.6m571.6m536.9m647.3m726.8m

Cost of goods sold

207.2m236.5m229.3m230.1m231.4m230.5m249.3m274.2m258.4m242.2m264.9m253.6m254.3m243.9m280.0m326.2m

Gross profit

264.0m280.2m279.5m270.0m273.3m304.5m302.2m301.7m286.7m311.8m307.8m307.0m317.3m293.0m367.3m400.6m

Gross profit Margin, %

56%54%55%54%54%57%55%52%53%56%54%55%56%55%57%55%
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

113.1m28.1m122.2m365.6m

Depreciation and Amortization

131.8m142.9m148.7m138.1m

Inventories

(54.2m)(5.7m)(47.7m)(12.9m)24.2m(52.1m)

Accounts Payable

28.6m30.1m7.8m(45.6m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

12.3m30.3m48.7m12.4m17.4m44.8m656.8m924.8m1.2b865.2m1.5b1.2b

Depreciation and Amortization

34.1m71.7m110.2m33.7m70.7m106.1m34.3m68.7m103.6m32.9m66.1m99.8m

Inventories

(34.4m)(51.0m)(67.9m)(26.9m)(37.9m)(56.2m)(16.9m)(11.7m)(26.3m)(11.6m)(8.0m)(14.5m)(13.7m)(79.8m)(83.5m)5.8m

Accounts Payable

(47.7m)(32.6m)(4.6m)(61.2m)(24.2m)(19.1m)(47.4m)(43.7m)(43.1m)20.6m(23.0m)(24.6m)
show all
USDFY, 2015

Revenue/Employee

259.9k

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.5 x
Show all financial metrics

Bio-Rad Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018

Products

8 k8 k9 k9 k

Products (Life Science)

5 k5 k6 k6 k

Products (Clinical Diagnostics)

3 k3 k3 k3 k

Clinical Diagnostic Tests Covered

300300300300
Show all operating metrics

Bio-Rad Acquisitions / Subsidiaries

Company NameDateDeal Size
CelseeApril 09, 2020
Raindance Technologies LimitedJanuary 16, 2017$87 m
GnuBIO Inc.April 14, 2014$50.4 m
Bio-Rad AbD Serotec GmbHJanuary 10, 2013€53 m
QuantaLifeOctober 05, 2011$162 m
DiaMed Holding AGMay 16, 2007$392.6 m
Blackhawk BiosystemsOctober 16, 2006
MJ GeneWorksJune 02, 2004$47 m
Bio-Metrics, Limited
Bio-Metrics Properties Limited
Show more

Bio-Rad Revenue Breakdown

Embed Graph

Bio-Rad revenue breakdown by business segment: 37.6% from Life Science, 61.7% from Clinical Diagnostics and 0.7% from Other

Bio-Rad revenue breakdown by geographic segment: 6.0% from Other (primarily Canada and Latin America), 37.7% from United States, 21.6% from Pacific Rim and 34.6% from Europe

Bio-Rad Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

Learn more about our premium products
SecurityScorecard logo

Bio-Rad Online and Social Media Presence

Bio-Rad's Trends

Embed Graph

Bio-Rad Company Culture

  • Overall Culture

    D+

    62/100

  • CEO Rating

    F

    40/100

  • Compensation

    C-

    60/100

Learn more on Comparably

Bio-Rad News and Updates

August 27, 2021

dPCR Market to Register $ 695.07mn growth during 2021-2025|Featuring Avance Biosciences Inc., Becton Dickinson and Co., and Bio-Rad Laboratories Inc. | 17000+ Technavio Reports

NEW YORK, Aug. 27, 2021 /PRNewswire/ -- The dPCR market has the potential to grow by USD 695.07 million during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 25.17% Understand the driving forces behind dPCR Market and target Potential Customers Here. Fetch Free...
August 05, 2021

Nuvia HR-S reduces aggregate content and separates closely related species

Learn how Nuvia HR-S reduces aggregate content and separates closely related species. We'll also show how on-column aggregate formation depends on the resin type & the resin’s interactions with the mAb.
July 29, 2021

Bio-Rad Reports Second-Quarter 2021 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2021.
July 27, 2021

Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Bio-Rad and 10x Genomics, Inc. (Nasdaq: TXG) have reached a final settlement to resolve multiple long-running litigations in Massachusetts, Delaware, Calif…
July 14, 2021

Bio-Rad to Report Second-Quarter 2021 Financial Results, Thursday, July 29, 2021

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2021 on Thursday, July 29, 2021, following the close of the market. The company will discuss these results in a conference …
June 30, 2021

Bio-Rad Announces Partnership with Seegene for Molecular Diagnostic Testing Products

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced a partnership with Seegene, Inc., a global leader in multiplex molecular diagnostics, for the clinical development and commercialization of infectious disease m…
Show more

 Bio-Rad Frequently Asked Questions

  • When was Bio-Rad founded?

    Bio-Rad was founded in 1952.

  • Who are Bio-Rad key executives?

    Bio-Rad's key executives are Norman Schwartz, Michael Crowley and Tim Ernst.

  • How many employees does Bio-Rad have?

    Bio-Rad has 8,000 employees.

  • What is Bio-Rad revenue?

    Latest Bio-Rad annual revenue is $2.5 b.

  • What is Bio-Rad revenue per employee?

    Latest Bio-Rad revenue per employee is $318.2 k.

  • Who are Bio-Rad competitors?

    Competitors of Bio-Rad include DiaSorin, Qiagen and Siemens Healthineers.

  • Where is Bio-Rad headquarters?

    Bio-Rad headquarters is located at 1000 Alfred Nobel Dr, Hercules.

  • Where are Bio-Rad offices?

    Bio-Rad has offices in Hercules, Villa Ortúzar, Gladesville, Wien and in 64 other locations.

  • How many offices does Bio-Rad have?

    Bio-Rad has 73 offices.